Authorized Generics as Manufacturer Response to Medicaid Rebate Cap Removal

This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

from JAMA Health Forum New Online https://ift.tt/avJnQAV

Comments

Popular posts from this blog

Skilled Nursing Facilities and Sufficient Bed Capacity